Successful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report

ABSTRACT Introduction Enfortumab vedotin plus pembrolizumab (EV + P) shows high efficacy in metastatic urothelial carcinoma (mUC), potentially increasing tumor lysis syndrome (TLS) risk. Case Presentation A 64‐year‐old man with mUC underwent surgery and adjuvant nivolumab after neoadjuvant chemother...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Daigo Takemori, Ryu Shigehisa, Sho Shimasaki, Erika Yamashita, Yoshitaka Kurano, Kaya Atagi, Yuhi Ota, Shinkuro Yamamoto, Hiroto Osakabe, Tomoya Nao, Tsutomu Shimamoto, Hideo Fukuhara, Nobutaka Shimizu, Satoshi Fukata, Shingo Ashida, Keiji Inoue
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wiley 2025-09-01
Serie:	IJU Case Reports
Ämnen:	enfortumab vedotin metastatic urothelial carcinoma pembrolizumab successful management tumor lysis syndrome
Länkar:	https://doi.org/10.1002/iju5.70069
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!